Plus Therapeutics Inc
PSTV0.569USD
+0.017+3.08%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
74.82MMarket Cap
LossP/E TTM
More Details of Plus Therapeutics Inc Company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Plus Therapeutics Inc Info
Ticker SymbolPSTV
Company namePlus Therapeutics Inc
IPO dateAug 09, 2000
CEOHedrick (Marc H)
Number of employees21
Security typeOrdinary Share
Fiscal year-endAug 09
Address4200 Marathon Blvd.
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78756
Phone17372557194
Websitehttp://www.plustherapeutics.com/
Ticker SymbolPSTV
IPO dateAug 09, 2000
CEOHedrick (Marc H)
Company Executives of Plus Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.11K
+781.79%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
139.33K
+375.08%
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.11K
+781.79%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
139.33K
+375.08%
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2018
By BusinessUSD
Name
Revenue
Proportion
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
By RegionUSD
Name
Revenue
Proportion
Japan
2.06M
77.05%
Americas
293.00K
10.97%
EMEA
270.00K
10.11%
Asia Pacific
50.00K
1.87%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
S.H.N. Financial Investments Ltd
1.09%
The Vanguard Group, Inc.
1.05%
Altium Capital Management LP
0.67%
Geode Capital Management, L.L.C.
0.59%
UBS Financial Services, Inc.
0.45%
Other
96.14%
Shareholders
Shareholders
Proportion
S.H.N. Financial Investments Ltd
1.09%
The Vanguard Group, Inc.
1.05%
Altium Capital Management LP
0.67%
Geode Capital Management, L.L.C.
0.59%
UBS Financial Services, Inc.
0.45%
Other
96.14%
Shareholder Types
Shareholders
Proportion
Investment Advisor
2.07%
Investment Advisor/Hedge Fund
1.70%
Corporation
1.09%
Individual Investor
0.31%
Hedge Fund
0.02%
Other
94.81%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
35
3.61M
7.19%
+1.73M
2025Q2
35
2.30M
3.80%
-2.38M
2025Q1
40
2.31M
11.85%
+1.40M
2024Q4
42
829.50K
14.07%
-98.90K
2024Q3
44
822.91K
13.96%
-122.82K
2024Q2
46
793.04K
13.90%
-131.21K
2024Q1
46
164.14K
3.77%
-119.25K
2023Q4
47
203.09K
4.50%
+1.47K
2023Q3
47
127.65K
2.90%
-110.39K
2023Q2
45
114.35K
4.03%
-124.09K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
S.H.N. Financial Investments Ltd
1.50M
1.51%
+614.55K
+69.40%
Aug 14, 2025
The Vanguard Group, Inc.
32.54K
0.03%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
51.18K
0.05%
-5.88K
-10.30%
Jun 30, 2025
UBS Financial Services, Inc.
87.64K
0.09%
+54.20K
+162.10%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.96K
0.01%
--
--
Jun 30, 2025
Hedrick (Marc H)
20.43K
0.02%
--
--
Jun 18, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Date
Type
Ratio
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
Apr 28, 2023
Merger
15→1
FAQs
Who are the top five shareholders of Plus Therapeutics Inc?
The top five shareholders of Plus Therapeutics Inc are:
S.H.N. Financial Investments Ltd holds 1.50M shares, accounting for 1.51% of the total shares.
The Vanguard Group, Inc. holds 32.54K shares, accounting for 0.03% of the total shares.
Geode Capital Management, L.L.C. holds 51.18K shares, accounting for 0.05% of the total shares.
UBS Financial Services, Inc. holds 87.64K shares, accounting for 0.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.96K shares, accounting for 0.01% of the total shares.
S.H.N. Financial Investments Ltd holds 1.50M shares, accounting for 1.51% of the total shares.
The Vanguard Group, Inc. holds 32.54K shares, accounting for 0.03% of the total shares.
Geode Capital Management, L.L.C. holds 51.18K shares, accounting for 0.05% of the total shares.
UBS Financial Services, Inc. holds 87.64K shares, accounting for 0.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.96K shares, accounting for 0.01% of the total shares.
What are the top three shareholder types of Plus Therapeutics Inc?
The top three shareholder types of Plus Therapeutics Inc are:
S.H.N. Financial Investments Ltd
The Vanguard Group, Inc.
Altium Capital Management LP
S.H.N. Financial Investments Ltd
The Vanguard Group, Inc.
Altium Capital Management LP
How many institutions hold shares of Plus Therapeutics Inc (PSTV)?
As of 2025Q3, 35 institutions hold shares of Plus Therapeutics Inc, with a combined market value of approximately 3.61M, accounting for 7.19% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 3.39%.
What is the biggest source of revenue for Plus Therapeutics Inc?
In FY2018, the Consumable business generated the highest revenue for Plus Therapeutics Inc, amounting to 2.17M and accounting for 81.21% of total revenue.
